NYSEAMERICAN:LCTX Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis $1.00 +0.02 (+1.52%) Closing price 10/23/2026 04:10 PM EasternExtended Trading$1.00 0.00 (-0.10%) As of 10/23/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LCTX alerts:Sign Up Key Stats Today's Range$0.94▼$1.0250-Day Range$0.90▼$1.1652-Week Range$0.88▼$2.09Volume1.15 million shsAverage Volume1.50 million shsMarket Capitalization$252.91 millionP/E RatioN/ADividend YieldN/APrice Target$6.25Consensus RatingBuy Company Overview Lineage Cell Therapeutics, Inc. is a biotechnology company focused on developing allogeneic cell therapies for unmet medical needs. The company uses its proprietary cell differentiation and manufacturing technologies to create specialized human cells intended to replace, repair or support damaged tissues. Lineage’s lead program, OpRegen, is an investigational retinal pigment epithelium cell replacement therapy being developed for geographic atrophy, an advanced form of dry age-related macular degeneration. The company has also developed cell therapy programs targeting neurological and sensory conditions, including oligodendrocyte progenitor cells for spinal cord injury and auditory neuronal progenitor cells for hearing loss. Based in Carlsbad, California, Lineage conducts research and clinical development primarily in the United States and works with commercial and strategic partners to advance its programs. The company was formerly known as BioTime, Inc. and adopted the Lineage Cell Therapeutics name in 2019. Brian M. Culley serves as chief executive officer.AI Generated. May Contain Errors. Read More Lineage Cell Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreLCTX MarketRank™: 1.69587489889 of 5 starsLineage Cell Therapeutics scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.Upside PotentialLineage Cell Therapeutics has a consensus price target of $6.25, representing about 525.0% upside from its current price of $1.00.Amount of Analyst CoverageLineage Cell Therapeutics has received no research coverage in the past 90 days.Read more about Lineage Cell Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.07) to ($0.04) per share.Price to Book Value per Share RatioLineage Cell Therapeutics has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lineage Cell Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.28% of the float of Lineage Cell Therapeutics has been sold short.Short Interest Ratio / Days to CoverLineage Cell Therapeutics has a short interest ratio ("days to cover") of 15.75, which indicates bearish sentiment.Change versus previous monthShort interest in Lineage Cell Therapeutics has recently decreased by 1.27%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLineage Cell Therapeutics does not currently pay a dividend.Dividend GrowthLineage Cell Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 4 people have searched for LCTX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows2 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lineage Cell Therapeutics' insider trading history. Receive LCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LCTX Stock News HeadlinesAverage analyst price target for Lineage Cell Therapeutics rises 13.67% to ₪1,962.32October 4, 2026 | msn.comLineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing PlatformSeptember 8, 2026 | markets.ft.comBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.October 25 at 1:00 AM | Decentralized Masters (Ad)Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical RiskSeptember 1, 2026 | seekingalpha.comLineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | finance.yahoo.comLineage Cell Therapeutics Balances Progress and RiskAugust 12, 2026 | theglobeandmail.comLineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call TranscriptAugust 7, 2026 | seekingalpha.comLineage Cell Therapeutics maps COR1 path with 'thaw and inject' cell therapy planJuly 14, 2026 | msn.comSee More Headlines LCTX Stock Analysis - Frequently Asked Questions How have LCTX shares performed this year? Lineage Cell Therapeutics' stock was trading at $1.67 at the beginning of 2026. Since then, LCTX stock has decreased by 40.1% and is now trading at $1.00. How were Lineage Cell Therapeutics' earnings last quarter? Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.00. The business earned $1.07 million during the quarter, compared to analyst estimates of $1.84 million. Lineage Cell Therapeutics had a negative net margin of 246.58% and a negative trailing twelve-month return on equity of 73.06%. Read the conference call transcript. Who are Lineage Cell Therapeutics' major shareholders? Top institutional shareholders of Lineage Cell Therapeutics include Defender Capital LLC. (2.63%) and Red Crane Wealth Management LLC (0.20%). Insiders that own company stock include Broadwood Partners, LP, Brian M Culley, Don M Bailey and Jill Ann Howe. View institutional ownership trends. How do I buy shares of Lineage Cell Therapeutics? Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lineage Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lineage Cell Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), 9 Meters Biopharma (NMTR), Matinas Biopharma (MTNB), Intel (INTC) and Viking Therapeutics (VKTX). Company Calendar Last Earnings8/06/2026Today10/25/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LCTX's financial health is in the Yellow zone, according to TradeSmith. LCTX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:LCTX CIK876343 Webwww.lineagecell.com Phone(442) 287-8963Fax510-521-3389Employees77Year Founded1990Price Target and Rating Average Price Target for Lineage Cell Therapeutics$6.25 High Price Target$9.00 Low Price Target$3.00 Potential Upside/Downside+525.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.53 million Net Margins-246.58% Pretax Margin-285.75% Return on Equity-73.06% Return on Assets-30.87% Debt Debt-to-Equity RatioN/A Current Ratio6.61 Quick Ratio6.61 Sales & Book Value Annual Sales$14.56 million Price / Sales17.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book5.26Miscellaneous Outstanding Shares252,910,000Free Float190,439,000Market Cap$252.91 million OptionableNot Optionable Beta1.60 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NYSEAMERICAN:LCTX) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
